GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Wedgewood Partners Comments on Perrigo

August 31, 2012 | About:
Holly LaFon

Perrigo (PRGO) positively contributed to performance during the quarter after the Company reported a 32% increase in adjusted income from continuing operations and subsequently received FDA approval for five new prescription and over-the-counter (OTC) pharmaceuticals. Over $15 billion in OTC pharmaceuticals will lose patent protection over the next several years and Perrigo, as the largest manufacturer of private-label, OTC pharmaceuticals, will have ample opportunity to provide its value-added services to retailers around the globe. During the quarter, shares of the company traded to valuation levels that were not as attractive as they have been in the past, so we trimmed positions in Perrigo.

From Tony Guerrerio's second quarter letter.


Rating: 2.4/5 (8 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide